Reduced-dose zevalin™ radioimmunotherapy for relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL) patients with thrombocytopenia:: Report of interim results of a phase II trial.

被引：0
|
作者：
Witzig, TE
White, CA
Gordon, LI
Schilder, RJ
Wiseman, GA
Rimmer, A
Parker, E
Grillo-Lopez, AJ
机构：
[1] Mayo Clin, Rochester, MN USA
[2] Idec Pharmaceut Corp, San Diego, CA USA
[3] Northwestern Univ, Chicago, IL 60611 USA
[4] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA
来源：
BLOOD | 1999年 / 94卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
400
引用
收藏
页码：92A / 92A
页数：1
相关论文
共 50 条
  • [1] Reduced-dose Zevalin™ radioimmunotherapy (RIT) for patients with B-cell non-Hodgkin's lymphoma (NHL) and mild thrombocytopenia:: Biodistribution and dosimetry results.
    Wiseman, GA
    Sparks, RB
    White, CA
    Leigh, BR
    Erwin, WD
    Adams, GP
    Podoloff, DA
    Cutler, PD
    Silverman, DH
    Meredith, RF
    Dunn, WL
    Gordon, LI
    Grillo-Lopez, AJ
    JOURNAL OF NUCLEAR MEDICINE, 2000, 41 (05) : 30P - 30P
  • [2] Zevalin™ radioimmunotherapy can be safely administered to patients with relapsed or refractory, B cell non-Hodgkin's lymphoma (NHL).
    Witzig, TE
    White, CA
    Gordon, LI
    Wiseman, GA
    Emmanouilides, C
    Murray, JL
    Lister, J
    Multani, PS
    BLOOD, 2001, 98 (11) : 606A - 606A
  • [3] Zevalin radioimmunotherapy is safe and well tolerated in patients with relapsed or refractory, B cell non-Hodgkin's lymphoma (NHL).
    Witzig, TE
    Gordon, LI
    Wiseman, GA
    Spies, S
    Emmanouilides, C
    Czuczman, MS
    Flinn, IW
    Barlett, NL
    Murray, JL
    Alkuzweny, B
    Multani, PS
    Grillo-López, AJ
    White, CA
    BLOOD, 2000, 96 (11) : 731A - 731A
  • [4] Radioimmunotherapy with 131I-rituximab for patients with relapsed/refractory B-cell non-Hodgkin's lymphoma (NHL)
    Kang, Hye J.
    Lee, Seung S.
    Kim, Kyeong M.
    Choi, Tae H.
    Cheon, Gi J.
    Kim, Won S.
    Suh, Cheolwon
    Yang, Sung H.
    Lim, Sang M.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2011, 7 (02) : 136 - +
  • [5] A ramdomized controlled trial of Zevalin™ radioimmunotherapy (RIT) for B-cell non-Hodgkin's lymphoma (NHL):: Biodistribution and dosimetry results.
    Wiseman, GA
    Sparks, RB
    Leigh, BR
    Erwin, WD
    Podoloff, DA
    Bartlett, NL
    Kornmehl, E
    Lomonica, D
    Dunn, WL
    Rosenberg, J
    Grillo-Lopez, AJ
    White, CA
    JOURNAL OF NUCLEAR MEDICINE, 2000, 41 (05) : 29P - 29P
  • [6] Radioimmunotherapy for patients with relapsed B-cell non-Hodgkin lymphoma
    Witzig, TE
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2001, 48 (Suppl 1) : S91 - S95
  • [7] Radioimmunotherapy for patients with relapsed B-cell non-Hodgkin lymphoma
    Thomas E. Witzig
    Cancer Chemotherapy and Pharmacology, 2001, 48 : S91 - S95
  • [8] Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia:: a phase II multicenter trial
    Wiseman, GA
    Gordon, LI
    Multani, PS
    Witzig, TE
    Spies, S
    Bartlett, NL
    Schilder, RJ
    Murray, JL
    Saleh, M
    Allen, RS
    Grillo-López, AJ
    White, CA
    BLOOD, 2002, 99 (12) : 4336 - 4342
  • [9] REPEATED RADIOIMMUNOTHERAPY (RIT) WITH I-131 RITUXIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN'S LYMPHOMA (NHL); PRELIMINARY RESULTS
    Kang, H. J.
    Lim, S. M.
    Cheon, G. J.
    Choi, C. W.
    Lee, S. S.
    Na, I. I.
    Ryoo, B. Y.
    Kim, W. S.
    Nam, S. H.
    Park, Y. H.
    Suh, C.
    Eom, H. S.
    Yang, S. H.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 100 - 100
  • [10] REPEATED RADIOIMMUNOTHERAPY (RIT) WITH I-131 RITUXIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN'S LYMPHOMA (NHL); PRELIMINARY RESULTS
    Kang, H. J.
    Lim, S. M.
    Cheon, G. J.
    Choi, C. W.
    Lee, S. S.
    Kim, W. S.
    Park, Y. H.
    Ryoo, B.
    Na, I. I.
    Yang, S. H.
    ANNALS OF ONCOLOGY, 2008, 19 : 232 - 232
12345